Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT Neoadjuvant TNBC Vaccine
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Intramuscular, Oral
01
Overview
The NANT Neoadjuvant TNBC Vaccine is an investigational, molecularly informed multi-agent neoadjuvant immunotherapy regimen developed by ImmunityBio for previously untreated stage II or III triple-negative breast cancer. In the withdrawn Phase 2 QUILT-3.057 study, the regimen combined metronomic cytotoxic chemotherapy, antigen-directed yeast and adenoviral-vector therapeutic cancer vaccines, the IL-15 superagonist ALT-803, haNK allogeneic natural killer cells, and the anti-PD-L1 antibody avelumab. Its intended strategy was to promote immunogenic tumor-cell death, induce antigen-specific T-cell responses, activate NK and T cells, and relieve PD-L1-mediated immune suppression before surgery. ([ctv.veeva.com](https://ctv.veeva.com/study/quilt-3057-nant-neoadjuvant-triple-negative-breast-cancer-tnbc-vaccine))
- Other names
- NANT Neoadjuvant TNBC VaccineNANT Neoadjuvant Triple-Negative Breast Cancer Vaccine
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)TUBB (Tubulin (alpha and beta subunits))MHC I (MHC class I})
Beyond the preview
Go deeper on NANT Neoadjuvant TNBC Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT Neoadjuvant TNBC Vaccine.